AzTrials
AzTrials

Alcohol Use Disorder (AUD)NCT07755046

Repetitive Transcranial Magnetic Stimulation for Alcohol Use Disorder

A study testing Repetitive transcranial magnetic stimulation in people with Alcohol Use Disorder (AUD) and Alcoholism, run by Ting-Gang Chang at 1 site in Taiwan.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study looked at whether repetitive transcranial magnetic stimulation (rTMS), a non-invasive brain stimulation treatment, could help adults with alcohol use disorder when added to their usual treatment. Read more about this study

Who is it for?
Ages 20 to 65 years
Conditions the study is for
Alcohol Use Disorder (AUD), Alcoholism
What is being tested?
Repetitive transcranial magnetic stimulation
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
9 participants
Where
1 siteTaiwan
Study dates
10 Jun 2025to 14 Jun 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adults aged 20 to 65 years
  • Diagnosis of alcohol use disorder according to DSM-5 criteria
  • Able to provide written informed consent and complete study procedures

Who cannot join

  • Moderate to severe alcohol withdrawal
  • Psychiatric symptoms interfering with alcohol use disorder treatment
  • Acute physical illness requiring hospitalization
  • Standard contraindications to repetitive transcranial magnetic stimulation
  • Pregnancy or planned pregnancy within one year
  • Formal disability certification related to a psychiatric disorder

Trial locations and contacts

1 site in 1 country.

Taiwan1 site
  • Taichung Veterans General Hospital, Taiwan

    Taichung, Taiwan, 407219

Other trials in Taiwan

About this study

Official title: Therapeutic Effects of Repetitive Transcranial Magnetic Stimulation on Alcohol Use Disorder: A One-Year, Randomized, Double-Blind MRI Tracking Study

This study looked at whether repetitive transcranial magnetic stimulation (rTMS), a non-invasive brain stimulation treatment, could help adults with alcohol use disorder when added to their usual treatment. Nine adults receiving abstinence-oriented care received 10 sessions of stimulation over the right front part of the brain. Drinking severity, mood, craving and quality of life were assessed before treatment, immediately after the 10 sessions, and again at one and three months. Brain scans were also obtained at these visits to examine whether stimulation was associated with changes in brain connections. The study had no comparison group, so the results cannot show whether any change was caused by the stimulation.

Read the detailed description

This was a single-arm, open-label pilot study conducted at a single medical centre in Taiwan. Adults aged 20 to 65 years with DSM-5 alcohol use disorder were enrolled during inpatient or outpatient abstinence-oriented care, after the treating physician confirmed that acute withdrawal had stabilized.

Stimulation was delivered over the right dorsolateral prefrontal cortex at the F4 position using a Magstim Rapid2 system with a figure-of-eight D70 mm air film coil: 10 sessions at 10 Hz and 110% of the visually determined resting motor threshold, 60 trains of five seconds each, 3,000 pulses per session over approximately 30 minutes, delivered on consecutive weekdays. Concomitant pharmacological and psychosocial treatment continued as usual care and was not protocolized.

Assessments were conducted at baseline, after the tenth session, and at one and three months, and comprised clinical measures (Alcohol Use Disorders Identification Test, Patient Health Questionnaire-9, craving visual analogue scales, WHOQOL-BREF) and multimodal magnetic resonance imaging (resting-state functional MRI, diffusion tensor imaging and magnetic resonance spectroscopy).

The study was originally approved as a one-year, randomized, double-blind, sham-controlled trial with a larger planned sample. Funding constraints and difficulty recruiting this population prevented completion of that design, and the study was conducted as a single-arm, open-label pilot with follow-up to three months. The trial was registered retrospectively.

Being tested
Repetitive transcranial magnetic stimulation
Keywords
Repetitive transcranial magnetic stimulation, Dorsolateral prefrontal cortex, Alcohol Use Disorders Identification Test, Resting-state functional MRI, Diffusion tensor imaging, Magnetic resonance spectroscopy, Pilot study
Medical subject headings
Alcoholism

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Repetitive transcranial magnetic stimulationDevice

    High-frequency repetitive transcranial magnetic stimulation

Study groups in NCT07755046
Study groupRoleWhat they receive
Active rTMSExperimentalTen sessions of active repetitive transcranial magnetic stimulation over the right dorsolateral prefrontal cortex (F4), at 10 Hz and 110% of the visually determined resting motor threshold, 60 trains of five seconds each, 3,000 pulses per session over approximately 30 minutes, delivered on consecutive weekdays. All participants received active stimulation in addition to usual abstinence-oriented care, which included pharmacological and psychosocial treatment that was not protocolized.
Receives: Device: Repetitive transcranial magnetic stimulation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Alcohol Use Disorders Identification Test (AUDIT) total score

    AUDIT total score, range 0 to 40, with higher scores indicating more severe alcohol-related problems. Change from baseline was assessed at each follow-up.

    Measured: Baseline, after the tenth stimulation session (median 2 days), 1 month, and 3 months

Secondary outcomes (7)
  1. Change in Patient Health Questionnaire-9 (PHQ-9) score

    PHQ-9 total score, range 0 to 27, higher scores indicating more severe depressive symptoms.

    Measured: Baseline, after the tenth stimulation session (median 2 days), 1 month, and 3 months

  2. Change in craving visual analogue scale score

    Visual analogue scale, range 0 to 10, higher scores indicating stronger craving.

    Measured: Baseline, after the tenth stimulation session (median 2 days), 1 month, and 3 months

  3. Change in WHOQOL-BREF total score

    WHOQOL-BREF (Taiwan version) total score, higher scores indicating better quality of life.

    Measured: Baseline, after the tenth stimulation session (median 2 days), 1 month, and 3 months

  4. Change in resting-state functional connectivity

    Whole-brain and network-level functional connectivity derived from resting-state functional MRI using the Schaefer 100-parcel, seven-network atlas.

    Measured: Baseline, after the tenth stimulation session (median 2 days), 1 month, and 3 months

  5. Change in white matter diffusion metrics

    Fractional anisotropy and mean diffusivity derived from diffusion tensor imaging.

    Measured: Baseline, after the tenth stimulation session (median 2 days), 1 month, and 3 months

  6. Change in brain metabolite concentrations

    Metabolite concentrations measured by single-voxel magnetic resonance spectroscopy.

    Measured: Baseline, after the tenth stimulation session (median 2 days), 1 month, and 3 months

  7. Adverse events

    Adverse events elicited by open-ended enquiry at each stimulation session and imaging visit.

    Measured: Throughout the stimulation course and follow-up, up to 3 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Aug 2026
  2. Study start10 Jun 2025
  3. Primary completion14 Jun 2026
  4. Study completion14 Jun 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
Originally designed as a two-arm, randomized, double-blind, sham-controlled trial. Funding constraints and recruitment difficulty prevented completion of that design; all enrolled participants received active stimulation and the study was conducted as a single-arm, open-label pilot.
Masking
None (open label)
Enrolment
9 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07755046
Sponsor's protocol ID
SF24002C
Other IDs
NSTC 113-2314-B-075A-006
Status last verified
Aug 2026
First submitted
5 Aug 2026
Last updated
10 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Individual-level data are not publicly available given the small sample and the potentially identifiable nature of the clinical data; de-identified data and analysis code may be made available by the corresponding author on reasonable request, subject to institutional review board approval.

Questions about this trial

What is this clinical trial studying?

A study testing Repetitive transcranial magnetic stimulation in people with Alcohol Use Disorder (AUD) and Alcoholism, run by Ting-Gang Chang at 1 site in Taiwan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Alcohol Use Disorders Identification Test (AUDIT) total score (time frame: Baseline, after the tenth stimulation session (median 2 days), 1 month, and 3 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in